Malignancy Rates in Brodalumab Clinical Studies for Psoriasis

BACKGROUND: Brodalumab is a fully human anti–interleukin-17 receptor A monoclonal antibody efficacious for the treatment of adults with moderate-to-severe plaque psoriasis. OBJECTIVE: This study summarizes malignancy rates in psoriasis clinical studies of brodalumab. METHODS: Data were pooled from o...

Descripción completa

Detalles Bibliográficos
Autores principales: Gottlieb, Alice, Lebwohl, Mark, Liu, Clive, Israel, Robert J., Jacobson, Abby
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275023/
https://www.ncbi.nlm.nih.gov/pubmed/32207067
http://dx.doi.org/10.1007/s40257-020-00512-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275023/
https://www.ncbi.nlm.nih.gov/pubmed/32207067
http://dx.doi.org/10.1007/s40257-020-00512-4

Ejemplares similares